NEFL and Alzheimer disease: We noted that CSF NfL levels were significantly elevated in the preclinical AD group (A+T-/N±) and distinguished preclinical AD participants from those with normal AD biomarkers (A-T-/N-) with an acceptable diagnostic accuracy (AUC 0.79).